Capping the commerce margin on oxygen concentrators by the federal government has resulted in guaranteeing client financial savings as the worth of the important gadget has come down, the Ministry of Chemicals and Fertilizers mentioned on Friday.
On June 3, the National Pharmaceutical Pricing Authority (NPPA) capped the commerce margin on oxygen concentrators at 70 per cent on the worth to distributor (PTD) stage.
In accordance with it, “a total of 104 manufacturers / importers of oxygen concentrators have submitted revised MRP for 252 products/brands,” it mentioned.
Downward revision in worth by as much as 54 per cent has been reported in 70 manufacturers, displaying discount in most retail worth by as much as Rs 54,337 per unit. Further, 58 manufacturers have reported worth discount of as much as 25 per cent and 11 manufacturers reported worth discount of 26-50 per cent, the assertion mentioned.
“Out of 252 products/brands reported, 18 products/brands reported by the domestic manufacturers did not show any decline in prices,” it added.
The commerce margin rationalisation for oxygen concentrators has resulted in guaranteeing client financial savings by eliminating unreasonable revenue margins in imported merchandise, the Ministry mentioned.
The revised MRP efficient from June 9, 2021 on all of the manufacturers and specs has been shared with the State Drug Controllers for strict monitoring and enforcement, it added.
“In order to monitor availability, the manufacturers / importers of oxygen concentrators have been directed to submit monthly stock details,” the assertion mentioned.
Oxygen concentrator is a non-scheduled drug and presently below the voluntary licensing framework of Central Drugs Standard Control Organisation (CDSCO).
In February 2019, NPPA had efficiently capped the commerce margin on anti-cancer medication.